IMPORTANCE Recent increases in US opioid-related deaths underscore the need to understand drivers of fatal overdose. The initial prescription of opioids represents a critical juncture because it increases the risk of future opioid use disorder and is preventable.
O pioids have helped physicians ameliorate suffering experienced by patients with pain, but the increase in opioid-related deaths has called into question physician prescribing patterns and their role in the epidemic. [1] [2] [3] In 2015, opioid overdose accounted for 33 000 deaths in the United States (approximately 91 deaths per day), and the US Centers for Disease Control and Prevention (CDC) estimates that nearly half of these deaths involved a prescription opioid. 4 Such data underscore the need to understand the drivers of fatal overdose. 4 Although many social, economic, and cultural factors have influenced the increase in opioid-related deaths, evidence suggests that physician overprescribing has also contributed. 5, 6 Such patterns indicate an urgent need to understand the association between clinical practice patterns and risk of opioid-related morbidity and mortality. The initial prescription of opioids among opioid-naive patients represents a particularly important juncture in medical decision making because it increases the risk of future opioid use disorder and is preventable. Fatal overdoses seem to cluster among patients who concurrently use benzodiazepines and opioids; these patients are up to 4 times more likely to overdose than patients not concurrently using benzodiazepines. [7] [8] [9] Although few policies have been able to curb the increase in opioid-related deaths, access to naloxone is emerging as a strategy to reverse fatal overdose, particularly in patients who are long-term users of opioids. [10] [11] [12] [13] However, little guidance exists to inform evidence-based prescribing.
In this context, we estimated US national patterns in new opioid prescribing in patients at increased risk of overdose from benzodiazepine use. We also examined coprescriptions of naloxone to assess the degree to which clinicians are adopting this practice as a strategy to prevent opioid-related death. We hypothesized that although new opioid prescriptions would have decreased in recent years, they would remain disproportionately high for patients at increased risk of fatal overdose and that naloxone use would be low.
Methods

Data Collection
We analyzed data from adults 20 years or older from the 2005-2015 National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS; available through 2011), nationally representative surveys of ambulatory care. 14 We included all visits to office-based physicians and hospital-based outpatient clinics. The National Center for Health Statistics (NCHS) and the CDC conduct the NAMCS and NHAMCS in the United States annually. The NAMCS is conducted on a nationally representative sample of visits to office-based physicians, and the NHAMCS is conducted on a nationally representative sample of visits to hospital-based outpatient clinics and emergency departments. For both surveys, data are collected from the medical record on patients' symptoms, comorbidities, and demographic characteristics; physicians' diagnoses; medications ordered or provided; and medical services provided. This study was exempt from institutional review board review according to policies of the UCLA Office of the Human Research Protection Program.
Prescriptions for Opioids and Benzodiazepines
The NAMCS and NHAMCS capture whether a prescription is new or continued. Ambulatory visits with a new drug prescription therefore reflect the national volume of new prescriptions for that medication in ambulatory settings. Using this framework, we estimated the number of new opioid prescriptions by identifying ambulatory visits during which a new opioid prescription was provided to a patient not receiving any other opioids. We also identified whether benzodiazepines or naloxone were reported on the medication list during the same visit. All medications were identified using Multum Lexicon drug codes and NCHS generic codes (eTable 1 in the Supplement). Visits for outpatient procedures that are frequently performed with sedation (eg, arthroscopy, endoscopy, surgery, and device insertion or removal) were excluded. We also excluded prescriptions for opioid-containing cough medicine and buprenorphine because they are not generally prescribed for pain. 15 A maximum of 8 medications could be recorded for visits between 2005 and 2011, which increased to 10 medications in 2012 to 2013 and 30 medications in 2014 to 2015. To maintain consistency, we limited our accounting to the first 8 medications for each visit across all years but performed a sensitivity analysis in which up to 30 medications were assessed. This sensitivity analysis is presented in eTable 2intheSupplement and yielded results similar to those of our primary analyses.
Pain-Related Reasons for Visit and Diagnoses
We reviewed all reasons for visit from 2005 to 2015 and identified reasons that were associated with pain. We then categorized these reasons for visit as being related to cancer, back pain, headache, injuries, musculoskeletal pain, or other causes of pain. In addition, we identified diagnosis codes for cancer, back pain, and headache. These codes are presented in eTable 3intheSupplement. The NAMCS and NHAMCS intake materials allowed physicians and staff to record up to 3 reasons for
Key Points
Question What are the national patterns in physician prescribing of opioids to patients at increased risk of overdose?
Findings In this study of 13 146 visits, representing 214 million visits nationally, with a new opioid prescription, rates of initial opioid prescribing to persons using benzodiazepines significantly increased from 2005 to 2010, followed by decreases through 2015. Higher rates of initial opioid prescriptions were seen among patients concurrently taking benzodiazepines compared with the general population.
Meaning Decreases in initial opioid prescriptions from 2010 to 2015 suggest that the recent increase in opioid-related deaths may be associated with factors other than physicians writing new opioid prescriptions; nevertheless, prescribing to higher-risk patients still occurred at rates higher than in the general population. 
Statistical Analysis
The reference populations used for calculating new opioid prescription rates were based on National Health and Nutrition Examination Survey (NHANES) data for 2005 to 2014 (2013-2014 NHANES data were carried forward to 2015 because 2015 data were unavailable). This method of analyzing NAMCS, NHAMCS, NHANES, and US Census Bureau data to generate population estimates has been used in prior research. [19] [20] [21] We estimated population rates rather than visit rates of new opioid prescriptions because the former is robust to differences in visit frequency between comparator groups and population estimates have greater US policy relevance. The NHANES asks participants if they have taken medications in the past 30 days for which they needed a prescription, and we separated patients who reported benzodiazepine use from those who did not. Because of the design of NHANES, our reference populations were defined by the cross-sectional point prevalence of benzodiazepine use rather than the period prevalence (cumulative prevalence) of benzodiazepine use during the year. 24 To compare visit rates of new opioid prescribing between patients prescribed or not prescribed benzodiazepines, we estimated generalized linear models using a Poisson distribution and log link function. The models adjusted for patients' clinical and demographic characteristics, insurance, region, and setting using data from 2010 to 2015 (after the inflection point for prescribing patterns). Subgroup analyses with tests for interaction were performed by sex, race/ethnicity, and age. All analyses accounted for the complex sampling design of NAMCS and NHAMCS and were performed using Stata, version 14 (StataCorp). 25 We used a 2-sided P < .05 to assess for statistical significance for all analyses.
Results
New Opioid Prescription Patterns
From 2005 to 2015, the annual number of US adults 20 years or older who reported using benzodiazepines increased from 7.3 million to 13.0 million, and the number who reported not using benzodiazepines increased from 202.8 million to 216.1 million. Patterns in new opioid prescriptions among these adults and adults in the general population are shown in (rate difference, −179; 95% CI, −310 to −48; P = .008). These rates were substantially higher than the rates of new opioid prescription in the general population not using benzodiazepines, which increased nonsignificantly from 78 to 93 per 1000 US persons between 2005 and 2010 (rate difference, 15; 95% CI, −3 to 33; P = .10) and decreased nonsignificantly to 79 per 1000 persons by 2015 (rate difference, −14; 95% CI, −38 to 11; P = .28). Naloxone was coprescribed in less than 1% of visits made by adults receiving a new opioid prescription and when a patient concurrently used a benzodiazepine. Table 1 compares the visit characteristics of US adults 20 years or older, stratified by whether these patients used a benzodiazepine. The unadjusted relative risk for initial opioid prescription among patients using a benzodiazepine compared with patients not prescribed a benzodiazepine was 1.74 (95% CI, 1.45-2.09; P < .001). The likelihood of receiving an initial opioid prescription remained higher for patients concurrently using benzodiazepines compared with the general popu- b P values calculated with Wald χ 2 test from simple ordinal (age and Charlson comorbidity index) or binomial or multinomial (sex, race/ethnicity, insurance, setting, and pain diagnosis) logistic regression models comparing patients prescribed vs not prescribed a benzodiazepine.
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Physician Table 2 ) after adjusting for demographic characteristics, comorbidities, and diagnoses associated with pain (adjusted relative risk, 1.83; 95% CI, 1.56-2.15; P < .001). In post hoc analyses, there was a significant interaction between initial opioid prescription among patients using a benzodiazepine and both race/ethnicity and age ( Figure 2 ).
Discussion
We found that in 2010, new opioid prescriptions for US adults stopped increasing and began to decrease among higher-risk patients who used benzodiazepines, with substantial decreases through 2015. These patterns suggest that the recent increase in opioid-related deaths may be associated with factors other than physicians writing new opioid prescriptions. Nevertheless, prescribing among higher-risk patients occurred at rates higher than rates in the general population. This finding represents an important opportunity to improve the quality of care for patients experiencing pain. These results may be of particular interest to psychiatrists because adults with chronic pain are substantially more likely to have mental illness, 26 and use of benzodiazepines, prescribed to approximately 1 in 12 US adults, is a risk factor for persistent opioid use after an initial prescription.
27-29
We observed a decrease in new opioid prescriptions from 2010 to 2015, with decreases among patients using a benzodiazepine in particular. This finding suggests that physicians writing new opioid prescriptions are not the primary driver of the recent increase in opioid-related deaths reported by the CDC. Opioid-related deaths have increased from 5 per 100 000 persons in the United States in 2005 to 7 per 100 000 persons in 2010 and 11 per 100 000 persons in 2015. 3 Although new opioid prescriptions increase the risk of opioid use disorder and high rates of new prescriptions before 2010 have likely contributed to current opioid use disorders, 5 overall prescriptions have been decreasing since 2010. Recent CDC data show increases in opioid-related overdose deaths even through 2017. 30 These increases have been associated with an increase in the rate of death from synthetic opioids, such as fentanyl, and a steady increase in heroin-related opioid deaths and deaths from natural and semisynthetic opioids, such as oxycodone. 31 Factors behind these concerning patterns include social networks of friends or relatives sharing opioids, patients with iatrogenic opioid use disorder who unintentionally overdose, and increasing availability of heroin or illicit synthetic opioids, such as illegally synthesized fentanyl. 30 These changes are also occurring against a broader backdrop of widening social, economic, and racial/ethnic disparities.
32-34
Our findings also show that rates of new prescriptions of opioids to patients prescribed benzodiazepines have remained disproportionately high from 2005 to 2015 compared with the general population receiving opioids alone. Concurrent benzodiazepine prescription with opioids has been associated with up to 4 times the risk of overdose death compared with prescription of opioids alone. [7] [8] [9] Because of these data, the CDC Guideline for Prescribing Opioids for Chronic Pain recommends that clinicians avoid prescribing opioids and benzodiazepines concurrently whenever possible. [11] [12] [13] Although chronic pain and mental illness frequently coexist, patients may garner greater benefit and less harm from nonbenzodiazepine and nonpharmacologic approaches to mental illness. In guidelines for chronic pain, the CDC recommends that clinicians consider offering naloxone to patients at increased risk for opioid overdose, including patients with concurrent benzodiazepine use. Many states now allow pharmacies to dispense naloxone without a written prescription, and 2 large national pharmacy chains recently announced that they would stock naloxone nasal spray in response to the increase in opioid overdose deaths. 37 We found that naloxone was rarely coprescribed during visits with an initial opioid prescription. Expanding access to naloxone at the community level may be a cost-effective policy option for reducing the rate of death from opioid overdoses. However, there is limited evidence on the effectiveness of prescribing naloxone for overdose prevention among patients receiving initial opioid prescriptions. Although the decrease of new opioid prescriptions is a step in the right direction, one danger to this pattern is that patients with chronic pain may lack care for their pain. In this context, our findings highlight an urgent need to reorganize our health care system's approach to managing pain. Multidisciplinary rehabilitation, acupuncture, yoga, and tai chi effectively alleviate chronic low back pain based on results of randomized clinical trials, but access and insurance coverage for such high-value treatments are frequently challenging in daily practice. 38, 39 Another approach for pain management is topical nonsteroidal anti-inflammatory pain medicines. Sixtyone randomized clinical trials have proven that these medicines can substantially reduce musculoskeletal pain with minimal risk of iatrogenic harm. 40 Despite this overwhelming evidence, many payers require physicians to complete prior-authorization applications for such medications while providing no such barriers for drugs such as oxycodone or lorazepam. Lack of insurance coverage may force patients to purchase these medicines out of pocket; generic diclofenac gel's lowest current out-of-pocket market price is approximately $45 per month compared with approximately $18 per month for oxycodone and approximately $9 per month for lorazepam. 41 We challenge policy makers, practice leaders, patients, clinicians, industry, and payers to develop innovative solutions that redesign our ability to deliver evidence-based, multidisciplinary, and low-risk approaches to chronic pain management.
26
Limitations
Our study has several limitations. The NAMCS and NHAMCS provide a limited amount of clinical information on each patient visit, and we were unable to robustly account for severity of pain, distinguish patients who received opioids for shortterm therapy from those who received opioids in the long term after their initial prescription, or distinguish patients with initial opioid prescriptions who had been treated with opioids in the past from patients who had not. We also did not have access to pharmacy data for the preceding months; thus, some patients with new prescriptions may have previously received opioid prescriptions that were discontinued or expired. The CIs for changes in population rates of new opioid prescriptions were also large because of sample size limitations. Overdose risk increases with benzodiazepine and opioid dose, but dose information was unavailable. Our estimates of medication prescriptions could also underestimate true rates because of underreporting. In addition, data from community health centers and outpatient hospital departments were unavailable from 2012 to 2015; thus, we performed adjustments to account for their absence. However, our 
